|
|
|
|
Captain Bisodol Rescues Indigestion and Heartburn Sufferers
5756 live jobs on PharmiWeb.com now Forest Laboratories, manufacturers of Bisodol, a leading indigestion and heartburn remedy has created Captain Bisodol, a brand mascot to help communicate the brands benefits to sufferers.
|
|
|
Poor Pozen
It's not often that you see a drug developer release data from two positive phase 3 trials for its lead pipeline compound and see its shares fall more than 4%, but that's what happened to Pozen (Nasdaq: POZN) yesterday.The good news is...
|
|
|
Addex Starts Phase IIb ADX10059, Proton Pump Inhibitor Combination Study in GERD Patients
- Addex Pharmaceuticals started a Phase IIb trial of ADX10059 as an add-on therapy to proton pump inhibitors (PPIs) for the treatment of gastroesophageal reflux disease (GERD), the cause of heartburn and other symptoms.The standard...
|
|
|
Meritage Pharma Aims to Develop Drug to Reduce Swelling in the Food Pipe
Biotech, Allergies, Esophagitis Luke Timmerman 12/3/08 Intense allergic reactions to things like bee stings or peanuts can be life-threatening because some people can suffocate from massive inflammation in the windpipe.But its a little...
|
|
|
Horizon Therapeutics announces HZT-501 trials meet primary endpoints
Horizon Therapeutics, Inc.has announced that two pivotal Phase 3 trials evaluating its lead investigational product candidate, HZT 501, met all primary endpoints.HZT 501, a novel, proprietary fixed-dose combination product containing...
|
|
|
Horizon Therapeutics Announces Two Pivotal HZT-501 Phase 3 Trials Meet Primary Endpoints
Pain / Anesthetics News Main Category: Pain / Anesthetics Also Included In: Clinical Trials / Drug Trials; Pharma Industry / Biotech Industry email to a friend printer friendly view / write opinions rate article Current Article Ratings:...
|
|
|
Horizon Therapeutics Announces Two Pivotal HZT-501 Phase 3 Trials Meet Primary Endpoints
Treatment demonstrates significant reduction in the incidence of NSAID-induced upper GI ulcers in patients with mild-to-moderate pain SKOKIE, Ill., Dec.2 /PRNewswire/ -- Horizon Therapeutics, Inc., a privately held biopharmaceutical...
|
|
|
Horizon Therapeutics Announces Two Pivotal HZT-501 Phase 3 Trials Meet Primary Endpoints
Treatment demonstrates significant reduction in the incidence of NSAID-induced upper GI ulcers in patients with mild-to-moderate pain SKOKIE, Ill., Dec.2 /PRNewswire/ -- Horizon Therapeutics, Inc., a privately held biopharmaceutical...
|
|
|
XenoPort shares dive on disappointing study
NEW YORK (AP) -- Shares of XenoPort Inc.plunged Tuesday after the biotechnology company said its heartburn drug candidate failed to improve severe heartburn symptoms in a midstage study. The stock plummeted $8.54, or 29.5...
|
|
|
Addex Starts Phase IIb ADX10059, Proton Pump Inhibitor Combination Study in GERD Patients
- Addex Pharmaceuticals (SWX:ADXN), the allosteric modulation company, started today a Phase IIb trial of ADX10059 as an add-on therapy to proton pump inhibitors (PPIs) for the treatment of gastroesophageal reflux disease (GERD), the cause...
|
|
|
Horizon Therapeutics Announces Two Pivotal HZT-501 Phase 3 Trials Meet Primary Endpoints
SKOKIE, Ill., Dec.2 /PRNewswire/ -- Horizon Therapeutics, Inc., a privately held biopharmaceutical company, today announced that two pivotal Phase 3 trials evaluating its lead investigational product candidate, HZT-501, met all primary...
|
|
|
Addex Pharmaceuticals (ADXN.SW) Starts Phase IIb ADX10059, Proton Pump Inhibitor Combination Study in GERD Pat
- Addex Pharmaceuticals (SWISS: ADXN), the allosteric modulation company, started today a Phase IIb trial of ADX10059 as an add-on therapy to proton pump inhibitors (PPIs) for the treatment of gastroesophageal reflux disease (GERD), the...
|
|
|
XenoPort Reports Results from a Phase 2 Clinical Trial of XP19986 as a Treatment for the Symptoms of Gastroeso
- XenoPort, Inc.(Nasdaq:XNPT) announced today top-line results from a Phase 2 clinical trial that examined the ability of XP19986 (arbaclofen placarbil) extended-release tablets to reduce symptoms experienced by subjects with...
|
|
|
Horizon Therapeutics Announces Two Pivotal HZT-501 Phase 3 Trials Meet Primary Endpoints
Treatment demonstrates significant reduction in the incidence of NSAID-induced upper GI ulcers in patients with mild-to-moderate pain SKOKIE, Ill., Dec.2 /PRNewswire/ -- Horizon Therapeutics, Inc., a privately held biopharmaceutical...
|
|
|
Finding, and Treating, Esophageal Cancer
Half a century ago, my grandmother died of esophageal cancer.For decades preceding her death, a bottle of milk of magnesia was her steady companion because she suffered daily from heartburn, now known as gastroesophageal reflux...
|
|
|
Horizon Therapeutics announces 2 pivotal HZT-501 Phase 3 trials meet primary endpoints
Horizon Therapeutics, Inc., a privately held biopharmaceutical company, today announced that two pivotal Phase 3 trials evaluating its lead investigational product candidate, HZT 501, met all primary endpoints.HZT 501, a novel,...
|
|
|
New techniques help in fight against esophageal cancer
Half a century ago, my grandmother died of esophageal cancer.For decades preceding her death, a bottle of milk of magnesia was her steady companion because she suffered daily from heartburn, now known as gastroesophageal reflux...
|
|
|
XenoPort Reports Results from a Phase 2 Clinical Trial of XP19986 as a Treatment for the Symptoms of Gastroeso
SANTA CLARA, Calif.--(BUSINESS WIRE)--XenoPort, Inc.(Nasdaq:XNPT - News) announced today top-line results from a Phase 2 clinical trial that examined the ability of XP19986 (arbaclofen placarbil) extended-release tablets to reduce...
|
|
|
Horizon Therapeutics Announces Two Pivotal HZT-501 Phase 3 Trials Meet Primary Endpoints
Treatment demonstrates significant reduction in the incidence of NSAID-induced upper GI ulcers in patients with mild-to-moderate pain SKOKIE, Ill., Dec.2 /PRNewswire/ -- Horizon Therapeutics, Inc., a privately held biopharmaceutical...
|
|
|
Addex Starts Phase IIb ADX10059, Proton Pump Inhibitor Combination Study in GERD Patients
- Addex Pharmaceuticals (SWX:ADXN), the allosteric modulation company, started today a Phase IIb trial of ADX10059 as an add-on therapy to proton pump inhibitors (PPIs) for the treatment of gastroesophageal reflux disease (GERD), the cause...
|
|
|
XenoPort Reports Results from a Phase 2 Clinical Trial of XP19986 as a Treatment for the Symptoms of Gastroeso
XenoPort, Inc.(Nasdaq:XNPT) announced today top-line results from a Phase 2 clinical trial that examined the ability of XP19986 (arbaclofen placarbil) extended-release tablets to reduce symptoms experienced by subjects with...
|
|
|
Addex Pharma initiates Phase IIb trial of ADX10059 as add-on therapy to PPIs for treatment of gastroesophageal
(RTTNews) - Addex Pharmaceuticals said it started a Phase IIb trial of ADX10059 as an add-on therapy to proton pump inhibitors, or PPIs, for the treatment of gastroesophageal reflux disease, the cause of heartburn and other symptoms.
|
|
|
Addex Starts Phase IIb ADX10059, Proton Pump Inhibitor Combination Study in GERD Patients
Francais (PDF): http://hugin.info/138017/R/1274456/283439.pdf Deutsch (PDF): http://hugin.info/138017/R/1274456/283440.pdf English (PDF): http://hugin.info/138017/R/1274456/283441.pdf Geneva, Switzerland, 2 December 2008 - Addex...
|
|
|
Addex Pharmaceuticals: Addex Starts Phase IIb ADX10059, Proton Pump Inhibitor Combination Study in GERD Patien
SOURCE: Addex Pharmaceuticals GENEVA, SWITZERLAND--(Marketwire - December 2, 2008) - Franais (PDF): http://hugin.info/138017/R/1274456/283439.pdf Deutsch (PDF): http://hugin.info/138017/R/1274456/283440.pdf English (PDF): http://hugin.info...
|
|
|
Scout Medical: The Device Incubator That Batted 3-For-3
Biotech, Devices, incubators Luke Timmerman 12/1/08 Everybody in the Seattle life sciences scene has heard about Accelerator, as a model for venture-backed incubators of promising biotech startups.But when the report cards come due on its...
|
